NetworkNewsBreaks – Why BriaCell Therapeutics Co
Post# of 69
BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF) is an immuno-oncology focused clinical-stage biotechnology company developing a proprietary targeted immunotherapy technology for advanced breast cancer. A recent article discussing the company reads: “The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX as a way to identify those patients most likely to respond.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer